Just came across this tidbit of info. Wonder if they are pissing in the wind like Cytori or if they will succeed where Cytori fails. Can anyone say failed Athena trials.
First participant treated in trial of stem-cell therapy for heart failure
April 18, 2017 by Gian Galassi
A research team at University of Wisconsin School of Medicine and Public Health has treated its first patient in an innovative clinical trial using stem cells for the treatment of heart failure that develops after a heart attack.
The trial is taking place at University Hospital, one of three sites nationwide currently enrolling participants. The investigational CardiAMP therapy is designed to deliver a high dose of a patient's own bone-marrow cells directly to the point of cardiac injury to potentially stimulate the body's natural healing response.
The patient experience with the trial begins with a cell-potency screening test. Patients who qualify for therapy are scheduled for a bone-marrow aspiration. The bone marrow is then processed on-site and subsequently delivered directly to the damaged regions in a patient's heart in a minimally invasive procedure.
"Patients living with heart failure experience a variety of negative symptoms that can greatly impact their day-to-day life," said UW Health cardiologist Dr. Amish Raval, associate professor of medicine and one of the principal investigators for the trial. "By being at the forefront of research for this debilitating condition, we look forward to studying the potential of this cell therapy to impact a patient's exercise capacity and quality of life."
The primary outcome to be measured is the change in distance during a six-minute walk 12 months after the initial baseline measurement.
Heart failure commonly occurs after a heart attack, when the heart muscle is weakened and cannot pump enough blood to meet the body's needs for blood and oxygen. About 790,000 people in the U.S. have heart attacks each year. The number of adults living with heart failure increased from about 5.7 million (2009-2012) to about 6.5 million (2011-2014), and the number of adults diagnosed with heart failure is expected to dramatically rise by 46 percent by the year 2030, according to the American Heart Association (AHA).
The CardiAMP Heart Failure Trial is a phase III study of up to 260 patients at up to 40 centers nationwide. Phase III trials are conducted to measure effectiveness of the intervention, monitor side effects and gather information for future use of the procedure. Study subjects must be diagnosed with New York Heart Association (NYHA) Class II or III heart failure as a result of a previous heart attack.
Information about eligibility or enrollment in the trial is available at
, or through a cardiologist.
Explore further: Stem cell patch shows early promise in treating heart failure
It would appear that stem cells are the way of the future. The question is whether CYTX with its systemic injection of ADRC as per the BARDA trial is the way to go in the burn indication?. Perhaps the stem cell gun can be used to spray on ADRC?. What intrigues me is the systemic application. We (I) was under the impression that all the regenerative cells are trapped in the lungs. Apparently this is not so. If we can treat scleroderma patients through a combination of both topical and systemic application then this would be a game changer as it could treat the lethal organ complications associated with the disease.
Perhaps it could also be applied to RA, Lupus, MS and OA sufferers also.
We need an approval in scleroderma (hand) indication. Only then will we be able to expect the market to take us seriously, and have the broader potential of ADRC reflected in the share price.
Curious how much they can treat with using as little as 1 square inch of skin to liberate the stem cells.
Otherwise, my quick look has me as impressed as Cytori's spray on app. In other words, no very.
Why did you think stem cells would get trapped in the lungs ? Other cells pass through.
Remember we have a solution that prevents clumping of the stem cells for the IV delivery.
Now treating specific organs with the IV delivery is where I believe the Azaya purchase may show its worth. To me, the biggest risk in the IV delivery is making sure the cells go where you want them to instead of treating some other injury weather acute or chronic. My loose understanding is with encapsulation you can target a area more specifically.